Oral TACH101 for Cancer
Trial Summary
What is the purpose of this trial?
This trial is testing a new oral medication called TACH101 in patients with advanced and metastatic solid tumors. Researchers aim to find the best dose that patients can handle and see if it can shrink or stop the tumors. They are also checking how safe the medication is for these patients.
Will I have to stop taking my current medications?
The trial requires that you stop any ongoing anticancer therapy at least 4 weeks or 5 half-lives before the first dose. Other medications are not specifically mentioned, so it's best to discuss with the trial team.
What data supports the effectiveness of the drug TACH101 for cancer treatment?
Eligibility Criteria
This trial is for adults with advanced or metastatic solid tumors, including gastrointestinal cancers and MSI-H colorectal cancer that didn't respond to standard treatments. Participants must have measurable disease, be in good physical condition (ECOG score 0-1), and meet specific blood count and organ function criteria. Women of childbearing potential must test negative for pregnancy and agree to use contraception.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive TACH101 in a 48-hour lead-in period followed by repeated dosing at different regimens in each 28-day cycle
Dose Expansion
Participants receive TACH101 at the RP2D identified in Phase 1a, with two cohorts enrolled: gastrointestinal cancers and MSI-H metastatic CRC
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- TACH101
Find a Clinic Near You
Who Is Running the Clinical Trial?
Tachyon Therapeutics, Inc.
Lead Sponsor